<?xml version="1.0" encoding="UTF-8"?>
<p id="p0030">Viral proteases are well validated drug targets that have led to various approved drugs, for example, against chronic infections with human immunodeficiency virus (HIV) or hepatitis C virus (HCV), which employ aspartyl and serine proteases, respectively.
 <xref rid="b0310" ref-type="bibr">
  <sup>62</sup>
 </xref> The SARS-CoV-2 M
 <sup>pro</sup> proteolytically cleaves the overlapping pp1a and pp1ab polyproteins to functional proteins (
 <xref rid="f0005" ref-type="fig">Fig. 1</xref>), which is a critical step during viral replication.
 <xref rid="b0145" ref-type="bibr">29</xref>, 
 <xref rid="b0315" ref-type="bibr">63</xref>, 
 <xref rid="b0320" ref-type="bibr">64</xref> Replication-essential enzymes such as RdRp or nsp13 cannot fully function without prior proteolytic release,
 <xref rid="b0280" ref-type="bibr">
  <sup>56</sup>
 </xref> positioning M
 <sup>pro</sup> as a key enzyme in the viral replication cycle. Consequently, its inhibition can stall the production of infectious viral particles and thus alleviate disease symptoms.
 <xref rid="b0115" ref-type="bibr">23</xref>, 
 <xref rid="b0250" ref-type="bibr">50</xref>, 
 <xref rid="b0325" ref-type="bibr">65</xref>, 
 <xref rid="b0330" ref-type="bibr">66</xref>, 
 <xref rid="b0335" ref-type="bibr">67</xref>, 
 <xref rid="b0340" ref-type="bibr">68</xref> Capitalising on knowledge gained on structure and inhibitors of M
 <sup>pro</sup> from previous epidemical coronaviruses, M
 <sup>pro</sup> is one of the most attractive viral targets for antiviral drug discovery against SARS-CoV-2.
</p>
